1. Dudzinski DM. Reflections on historical, scientific, and legal issues relevant to designing approval pathways for generic versions of recombinant protein–based therapeutics and monoclonal antibodies. Food Drug Law J. 2005;60(2):143–260.
2. Bhattacharyya L, Cecil T, Dabbah R, Roll D, Schuber S, Scheinin EB, et al. The value of USP public standards for therapeutic products. Pharm Res. 2004;21(10):1725–31.
3. USP. USP 34–NF 29, General Notices. Rockville, MD: USP; 2011:3–4,6.
4. SM Collaborative Group, Williams RL, Abernethy DR, Koch WF, Hauck WW, Cecil TL. Performance-based monographs. Pharmacopeial Forum. 2009;35(3):765–71.
5. Hauck WW, DeStefano AJ, Cecil TL, Abernethy DR, Koch WF, Williams RL. Acceptable, equivalent, or better: approaches for alternatives to official compendial procedures. Pharmacopeial Forum. 2009;35(3):772–8.